TheraCoat snags $7M for bladder drug delivery platform; Echo wins IRB approval for Symphony glucose monitoring system;

> TheraCoat, the developer of a delivery platform that improves drug infiltration in the internal cavity of the bladder, welcomed a $7 million investment from Pontifax, CHealth Fund and private investors. More

> Echo Therapeutics ($ECTE) received IRB approval of a clinical trial of its Symphony CGM System, a noninvasive, wireless, transdermal continuous glucose monitoring system. Release

> TriStar Wellness Solutions signed a three-year licensing agreement with Polytherapeutics to use TriStar's PharmaDur drug-delivery technology to treat specific skin conditions and wounds. Release

> Sunovion Pharmaceuticals reported clinical trial results of its Brovana Inhalation Solution for serious respiratory events in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The results supported the long-term safety profile of the inhaled solution. Release

> BioRestorative Therapies signed a consulting agreement with Dexterity to advance production of BRT's delivery device for intervertebral disc stem cell therapy, brtxDISC. Release

 

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.